Vitiligo

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 4, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Cream, American Academy of Dermatology, Safety, Randomness, Atopic dermatitis, Ageing, Autoimmunity, Treatment, Dermatology, Inflammation, AAD, Vitiligo, Prurigo, Hidradenitis suppurativa, Abstract, American Academy, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.
  • “We are pleased to convene at this year’s AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • “Our presence at this year’s meeting showcases Incyte’s commitment to find solutions for patients where there continues to be critical unmet needs.
  • They will also be published online via the Journal of the American Academy of Dermatology (JAAD) supplement in Fall 2024.

Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024

Retrieved on: 
Friday, March 8, 2024
Alopecia areata, Anxiety, Natural history, Psoriasis, Autoimmune disease, Professor, Assistant, Hair loss, Quality of life, Atopic dermatitis, Alopecia totalis, Skin, Mental, Entrepreneurship, RWE, Hashimoto's thyroiditis, AA, AAD, Vitiligo, University, Hidradenitis suppurativa, Patient, Disease, Dermatitis, Diagnosis, Social stigma, Depression, Nursing

DURHAM, N.C., March 8, 2024 /PRNewswire/ -- New patient-reported outcomes data presented at AAD 2024 from Target RWE's TARGET-DERM AA registry confirms the high unmet need and significant disease burden in patients with moderate to severe alopecia areata (AA). TARGET-DERM is the largest and most comprehensive longitudinal RWE study observing patients with immune-mediated inflammatory skin conditions in the United States.

Key Points: 
  • Patients with AA have a high unmet medical need due to comorbid conditions and high impact on quality of life.
  • The most common comorbid conditions associated with AA include vitiligo, atopic dermatitis (eczema), Hashimoto's thyroiditis, psoriasis, and systemic lupus erythematosus.
  • TARGET-DERM AA is distinctively positioned to address real-world access to care, disease progression, diagnosis, and treatment in patients with moderate to severe AA.
  • "What's important about our data presented at AAD and TARGET-DERM AA is that we are gaining insights on the impact of the disease.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024
Pharmaceutical, Health, Oncology, Other Health, Entrepreneurship, Vitiligo, Patient, Incyte, Therapy, Rheumatoid arthritis, JAK, Third Rock Ventures, Molecular biology, Pharmacology, Cancer, Medicine, Drug discovery, FGFR, Cholangiocarcinoma, Ruxolitinib, Non-small-cell lung cancer, COVID-19, Atopic dermatitis, PARP1, FDA, Polycythemia, Eli Lilly and Company, Medicinal chemistry, Drug, EVP, GPH, CNS, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Retrieved on: 
Wednesday, January 10, 2024
Vitiligo, Patient, Therapy, LEF1, MITF, Factorization of polynomials, Melanocyte, Skin, Safety, Protein, Inflammation, Biomarker, SOX10, BET, Pharmacokinetics, Week

The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.

Key Points: 
  • The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.
  • Positive clinical data from the Phase 1b trial were announced in October 2023.
  • One lesion, selected for treatment with VYN201, had skin tissue biopsies taken prior to first application of VYN201 and after 8 weeks of treatment.
  • “We are encouraged by these new biomarker data from the Phase 1b trial for VYN201, building on our recently announced positive clinical results,” said David Domzalski, President and CEO of VYNE.

AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update

Retrieved on: 
Wednesday, January 10, 2024
ASX, Vitiligo, Patient, Avita Medical, Commercial, Mental health, Quality of life, Disease, AVH, Growth, Pharmaceutical industry

“We have made tremendous progress over the last four quarters, with consecutive commercial revenue growth rates of 40%, 42%, 51%, and 50%, respectively, over the same periods in 2022.

Key Points: 
  • “We have made tremendous progress over the last four quarters, with consecutive commercial revenue growth rates of 40%, 42%, 51%, and 50%, respectively, over the same periods in 2022.
  • Key study endpoints include patient and clinician satisfaction of treatment, burden of disease, and patient mental health status.
  • The Company completed enrollment of TONE with 109 patients at investigational sites across the United States earlier than anticipated.
  • Patients will be followed for a 12-month period, with the primary follow-up period being 6-months after treatment.

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
Sale, Vitiligo, PIPE, Therapy, IND, Psoriasis, Patient, Rheumatoid arthritis, BET, Pharmaceutical industry

BRIDGEWATER, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and nine months ended September 30, 2023 and provided a business update.

Key Points: 
  • On track for VYN202 IND submission by year-end 2023, with plans to begin Phase 1a trial in Q1 2024
    BRIDGEWATER, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and nine months ended September 30, 2023 and provided a business update.
  • “We have made substantial progress in advancing our business in recent months,” said David Domzalski, President and Chief Executive Officer of VYNE.
  • “With positive results from our Phase 1b trial, we believe there is strong support to advance VYN201 as a potential category-leading therapy in the treatment of vitiligo.
  • VYNE expects to submit its IND for VYN202 by year-end 2023 and commence a first-in-human Phase 1a single ascending dose/multiple ascending dose trial in the first quarter of 2024.

Particle Size Analysis Market Worth $596 Million | MarketsandMarkets

Retrieved on: 
Thursday, November 16, 2023
Acne, Particle size, Vitiligo, Research, Competition, Mineral, Dermatology, Food, Investment, Psoriasis, Particle, Imaging particle analysis, Dynamic light scattering, Alopecia areata, Mining, FDA, TSI, SME, Quality control, Atopic dermatitis, Rosacea, Nanotechnology, Growth, Brookhaven Instruments, Shimadzu, Overalls, Adhesive, Retail, Cassette tape, Marketing

Based on the technology, the particle size analysis market is segmented into laser diffraction, dynamic light scattering, imaging, colter principle, nanoparticle tracking analysis, sieve analysis and other technologies.

Key Points: 
  • Based on the technology, the particle size analysis market is segmented into laser diffraction, dynamic light scattering, imaging, colter principle, nanoparticle tracking analysis, sieve analysis and other technologies.
  • The wet dispersion segment accounted for the largest share of the particle size analysis market, by dispersion in 2022.
  • Particle Size Analysis Market Dynamics:
    Key Market Players of Particle Size Analysis Industry:
    As of 2023, prominent players in the particle size analysis market are spectris (UK), HORIBA (Japan), Danaher (US), Anton Paar GmbH (Austria), Bettersize Instruments Ltd. (China), Brookhaven Instruments (US), Fritsch GmbH (Germany), LS Instruments (Switzerland), Metller Toledo (US), Micromeritics Instrument Corporation (US), Microtrac Retsch GmbH (Germany), Shimadzu Corporation (Japan), Sympatec GmbH (Germany), and TSI (US), and among others.
  • Particle Size Analysis Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall particle size analysis market and the subsegments.

Particle Size Analysis Market Worth $596 Million | MarketsandMarkets

Retrieved on: 
Thursday, November 16, 2023
Acne, Particle size, Vitiligo, Research, Competition, Mineral, Dermatology, Food, Investment, Psoriasis, Particle, Imaging particle analysis, Dynamic light scattering, Alopecia areata, Mining, FDA, TSI, SME, Quality control, Atopic dermatitis, Rosacea, Nanotechnology, Growth, Brookhaven Instruments, Shimadzu, Overalls, Adhesive, Retail, Cassette tape, Marketing

Based on the technology, the particle size analysis market is segmented into laser diffraction, dynamic light scattering, imaging, colter principle, nanoparticle tracking analysis, sieve analysis and other technologies.

Key Points: 
  • Based on the technology, the particle size analysis market is segmented into laser diffraction, dynamic light scattering, imaging, colter principle, nanoparticle tracking analysis, sieve analysis and other technologies.
  • The wet dispersion segment accounted for the largest share of the particle size analysis market, by dispersion in 2022.
  • Particle Size Analysis Market Dynamics:
    Key Market Players of Particle Size Analysis Industry:
    As of 2023, prominent players in the particle size analysis market are spectris (UK), HORIBA (Japan), Danaher (US), Anton Paar GmbH (Austria), Bettersize Instruments Ltd. (China), Brookhaven Instruments (US), Fritsch GmbH (Germany), LS Instruments (Switzerland), Metller Toledo (US), Micromeritics Instrument Corporation (US), Microtrac Retsch GmbH (Germany), Shimadzu Corporation (Japan), Sympatec GmbH (Germany), and TSI (US), and among others.
  • Particle Size Analysis Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall particle size analysis market and the subsegments.